ABSTRACT
The nasal route of drug delivery is convenient for administering active pharmaceutical agents. These agents can be for local therapy (e.g., established treatments such as corticosteroids for rhinitis) or for systemic therapy (e.g., new-generation migraine therapies such as Imigran™/ Imitrex™ [UK/U.S.]). Table 13.1 summarises a range of aqueous nasal products marketed in the United States and the United Kingdom. The number of active ingredients are relatively small and comprise both simple low molecular mass molecules and newer peptide molecules.
